MarketCap
Facebook
X
TelegramQuartalsbericht 2025-Q3
hinzugefügt 12.11.2025
ARCA biopharma Langfristige Verbindlichkeiten 2011-2026 | ABIO
Langfristige Verbindlichkeiten Jährlich ARCA biopharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 409 K | - | - | 20 K | 39 K | - | 3 K | 1 K | - | 16 K |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 409 K | 1 K | 81.3 K |
Langfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Grifols, S.A.
GRFS
|
7.22 B | $ 7.71 | 1.65 % | $ 6.83 B |  Spain |
 |
Altimmune
ALT
|
4.4 M | $ 3.5 | 4.64 % | $ 308 M |  USA |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B |  France |
 |
Ascendis Pharma A/S
ASND
|
101 M | $ 221.52 | -0.16 % | $ 5 B |  Danmark |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | France |
 |
Heron Therapeutics
HRTX
|
14.6 M | $ 0.8 | 2.5 % | $ 133 M | USA |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M |  Israel |
 |
Incyte Corporation
INCY
|
315 M | $ 90.82 | 0.04 % | $ 17.7 B | USA |
 |
Atreca
BCEL
|
12.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
78.7 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
InMed Pharmaceuticals
INM
|
338 K | $ 0.79 | -3.52 % | $ 1.93 M | Canada |
 |
INmune Bio
INMB
|
126 K | $ 1.23 | 5.13 % | $ 22.1 M | USA |
 |
Inovio Pharmaceuticals
INO
|
107 M | $ 1.57 | -0.95 % | $ 34.8 M | USA |
 |
Innate Pharma S.A.
IPHA
|
105 M | $ 1.34 | 14.26 % | $ 235 M | France |
 |
Calithera Biosciences
CALA
|
4.82 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
3.35 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
81.7 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
1.93 M | - | -74.18 % | $ 955 K | USA |
 |
Checkpoint Therapeutics
CKPT
|
2.47 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
579 M | - | -7.23 % | $ 13 M | USA |
 |
Inventiva S.A.
IVA
|
13.8 M | $ 6.09 | 5.36 % | $ 138 M | France |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
31.3 M | $ 2.13 | 1.91 % | $ 199 M | Israel |
 |
KalVista Pharmaceuticals
KALV
|
110 M | $ 16.93 | -0.41 % | $ 841 M | Britain |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
CorMedix
CRMD
|
924 K | $ 6.35 | 1.6 % | $ 457 K | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
25.6 M | $ 4.33 | 2.12 % | $ 719 M | Canada |
 |
Kamada Ltd.
KMDA
|
7.06 M | $ 8.33 | 0.97 % | $ 260 M | Israel |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |